Adverum Biotechnologies Inc. (NASDAQ: ADVM) Stock Information | RedChip

Adverum Biotechnologies Inc. (NASDAQ: ADVM)


$4.8450
+0.1450 ( +5.10% ) 74.6K

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Market Data


Open


$4.8450

Previous close


$4.7000

Volume


74.6K

Market cap


$99.02M

Day range


$4.5400 - $5.0530

52 week range


$4.5400 - $29.7000

SEC Filings


Form Type Description Pages Date
sc Insider transactions Dec 22, 2024
s-3 Registration statements Dec 22, 2024
sc Insider transactions Dec 22, 2024
sc Insider transactions Dec 22, 2024
effect Other Dec 22, 2024
sc Insider transactions Dec 22, 2024
corresp Comment letters Dec 22, 2024
424b3 Other Dec 22, 2024
corresp Comment letters Dec 22, 2024
s-8 Registration statements Dec 22, 2024

Latest News